Edward Mayerson

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)”.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990

N/A

4.8DataRank · unranked

160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1073

N/A

0DataRank · unranked

32 citations

Megan Othus, Sandip Pravin Patel, Young Kwang Chae, Kathy D. Miller, Rashmi Chugh +8 more

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5071

N/A

0DataRank · unranked

2 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5523

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +9 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more